Handelsbanken Fonder’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Handelsbanken Fonder’s Portfolio ARNA Stock Details ARNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-113,030	Closed	-$10.5M	–	1738
2021 Q4	$10.5M	Sell	113,030 -194,400	-63%	-$12.8M	0.05%	332
2021 Q3	$18.3M	Buy	307,430 +55,000	+22%	+$3.25M	0.1%	218
2021 Q2	$17.2M	Buy	252,430 +2,800	+1%	+$183K	0.09%	235
2021 Q1	$17.3M	Sell	249,630 -22,200	-8%	-$1.71M	0.1%	208
2020 Q4	$20.9M	Buy	271,830 +37,900	+16%	+$2.84M	0.13%	165
2020 Q3	$17.5M	Buy	233,930 +20,000	+9%	+$1.33M	0.13%	168
2020 Q2	$13.5M	Buy	213,930 +128,930	+152%	+$7.09M	0.11%	176
2020 Q1	$3.57M	Buy	85,000 +15,000	+21%	+$688K	0.08%	149
2019 Q4	$3.18M	Hold	70,000	–	–	0.06%	164
2019 Q3	$3.2M	Buy	+70,000	New	+$3.93M	0.06%	155

Handelsbanken Fonder's ARNA Position: Q1 2022 in Review

Handelsbanken Fonder sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 113,030 shares — an estimated $10.5M sold.

Handelsbanken Fonder first reported a position in ARNA in Q3 2019 and held it in 10 quarters. The position peaked at $20.9M in Q4 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.

Handelsbanken Fonder reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
Handelsbanken Fonder sold 113,030 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $10.5M.
Handelsbanken Fonder first reported a position in Arena Pharmaceuticals Inc in Q3 2019 and held it in 10 quarters.
Handelsbanken Fonder's Arena Pharmaceuticals Inc position peaked at $20.9M in Q4 2020.
1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.

Based on Handelsbanken Fonder's 13F filing for Q1 2022, filed 11 May 2022.